Core Viewpoint - China Nuclear International (02302) has seen a stock price increase of over 7%, currently at 7.23 HKD, with a trading volume of 12.73 million HKD. The company anticipates a revenue of no less than 2.46 billion HKD and a gross profit of at least 260 million HKD for the fiscal year 2025, indicating steady growth compared to 2024 [1] Revenue and Profit Forecast - The primary driver of revenue growth is identified as an increase in uranium trading transaction volume [1] - For 2024, the net profit attributable to the uranium trading business is projected to be approximately 140 million HKD, excluding factors such as the sale of subsidiary interests and joint venture performance [1] - The expected net profit from the uranium trading business for 2025 is projected to be no less than 190 million HKD, indicating a year-on-year increase of over 35% [1]

Group 1 - The core viewpoint of the article highlights that China Nuclear International (2302.HK) experienced a significant intraday increase of over 14%, reaching a peak of 7.2 HKD, with a year-to-date rise exceeding 50% [1] - The company issued a positive earnings forecast, expecting revenue for the fiscal year 2025 to increase to no less than approximately 2.46 billion HKD, with gross profit rising to no less than approximately 260 million HKD [1] - For the fiscal year 2024, the company recorded revenue and gross profit of approximately 1.841 billion HKD and 234 million HKD, respectively, indicating a substantial growth trajectory [1] Group 2 - The revenue growth is primarily attributed to an increase in uranium trading volumes, which includes transactions with independent third parties and a rise in ongoing related transactions [1] - The spot uranium prices are expected to remain relatively stable in the second half of 2024 and throughout 2025, allowing the company to increase uranium trading activities while maintaining controllable risk levels [1] - The uranium trading volume completed by the company for the fiscal year 2025 has already covered the demand for uranium products carried over from the fiscal year 2024 under the ongoing related transaction framework [1]